Yoshinobu Onuma1, MD, PhD; Bernard Chevalier2, MD; Masafumi Ono1,3, MD; Àngel Cequier4, MD; Dariusz Dudek5, MD; Michael Haude6, MD; Didier Carrié7, MD, PhD; Manel Sabaté 8, MD, PhD; Stephan Windecker9, MD; Richard R. Rapoza10, PhD; Nick E.J. West10,11, MA, MD; Sebastian Reith12,13, MD; Manuel de Sousa Almeida14, MD, PhD; Gianluca Campo15, MD; Andrés Íñiguez-Romo16, MD, PhD; Patrick W. Serruys1,17, MD, PhD
1. Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland; 2. Ramsay Générale de Santé, Institut Cardiovasculaire Paris Sud, Massy, France; 3. Amsterdam UMC, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands; 4. Bellvitge University Hospital, Barcelona, Spain; 5. Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 6. Städtisches Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany; 7. Department of Cardiology, CHU Rangueil, Toulouse, France; 8. Cardiovascular Institute, Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 9. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 10. Abbott Vascular, Santa Clara, CA, USA; 11. Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom; 12. Department of Cardiology, St. Franziskus Hospital Münster, Münster, Germany; 13. Department of Internal Medicine I, University Hospital of the RWTH Aachen, Aachen, Germany; 14. Department of Cardiology, Centro Hospital de Lisboa Ocidental, Lisbon, Portugal; 15. Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cone (FE), and Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA), Italy; 16. Hospital Alvaro Cunqueiro, Vigo, Spain; 17. NHLI, Imperial College London, London, United Kingdom
The Absorb™ bioresorbable everolimus-eluting scaffold (Abbott Vascular, Santa Clara, CA, USA) was designed to provide a transient vessel scaffold and everolimus elution followed by bioresorption of the polymer, aiming to restore coronary structure and functionality. Although randomised controlled trials comparing the bioresorbable scaffold with the XIENCE everolimus-eluting stent (Abbott Vascular) demonstrated non-inferiority of Absorb compared with XIENCE in target lesion failure (TLF) at one year, the excess of early, late, and very late scaffold thromboses raised safety concerns about the bioresorbable scaffold, leading to a halt of commercialisation of the product. Theoretically, device-related events should diminish ...